AccuType® IL28B
Also known as: Pegylated Interferon, Ribavirin, IL28 Polymorphism (rs12979860), Interleukin 28B, Hepatitis C (HCV)
Use
AccuType® IL28B identifies polymorphisms in the IL28B gene (now IFNL3) that have been associated with patient response to pegylated interferon‐plus‐ribavirin therapy for hepatitis C virus genotype 1 infection. These genetic markers help clinicians gauge the likelihood of achieving a sustained virologic response and may inform consideration of alternative antiviral regimens in clinical decision‐making.
Special Instructions
Physician attestation of informed consent is required when ordering this germline genetic test if the facility is located in certain states (e.g., AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD, VT) or if the test is performed in MA.
Limitations
Not provided.
Methodology
NGS
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Not provided.